<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779908</url>
  </required_header>
  <id_info>
    <org_study_id>F0101406</org_study_id>
    <secondary_id>B12-12-1095</secondary_id>
    <nct_id>NCT01779908</nct_id>
  </id_info>
  <brief_title>Role of Vitamin D in the Prevention and Treatment of Deseases Associated With Insulin Resistance</brief_title>
  <acronym>VIDIR</acronym>
  <official_title>Role of Vitamin D in the Prevention and Treatment of Deseases Associated With Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Québec, CHU de Québec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Québec, CHU de Québec</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized and placebo-controlled 6-month trial of vitamin D supplementation in
      144 Caucasian and vitamin D-deficient men and postmenopausal women aged of 50 years + with
      the hypertriglyceridemic waist phenotype and a BMI ≤40 kg/m2. Participants will be
      randomized by sex and BMI  The primary aim is to compare the effect of daily vitamin D3
      (cholecalciferol, 5000 IU) vs. placebo for 6 mo on insulin sensitivity (M-value by the gold
      standard method, the euglycemic hyperinsulinemic clamp). Secondary aims are to evaluate the
      effects of vitamin D3 vs. placebo on other indices of glucose metabolism, the lipid profile,
      blood pressure and anthropometric measurements. Questionnaires on physical activity and
      sunlight exposure, and a food frequency questionnaire will be administered at 0 and 6 mo to
      adjust for confounding factors. At 0 and 6 mo, biochemical markers associated with insulin
      sensitivity will be measured : changes in serum 25(OH)D with changes in blood markers
      associated with insulin sensitivity [hs-CRP, inflammatory cytokines (IL-6 and TNF-alpha),
      adiponectin, leptin, total and undercarboxylated osteocalcin].

      This research project intends to test 2 major hypotheses: (1) that vitamin D deficiency
      plays a causal role in the pathogenesis of insulin resistance in humans; and (2) that
      vitamin D increases insulin sensitivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Prospective, randomized and placebo-controlled 6-month trial of vitamin D
      supplementation in 144 Caucasian and vitamin D-deficient [serum 25(OH)D ≤50 nM] men and
      postmenopausal women aged of 50 years + with the hypertriglyceridemic waist phenotype (waist
      circumference above 90 cm + fasting triglycerides above 2.0 mM in men; waist circumference
      above 85 cm + fasting triglycerides above 1.5 mM in women) and a BMI ≤40 kg/m2. Participants
      will be randomized by sex and BMI (&lt;30 kg/m2 vs. above 30 kg/m2). The primary aim is to
      compare the effect of daily vitamin D3 (cholecalciferol, 5000 IU) vs. placebo for 6 mo on
      insulin sensitivity (M-value by the gold standard method, the euglycemic hyperinsulinemic
      clamp). Secondary aims are to evaluate the effects of vitamin D3 vs. placebo on other
      indices of glucose metabolism (fasting glucose, 2-h plasma glucose post OGTT, HbA1c, insulin
      sensitivity index (HOMA-IS using fasting glucose and insulin), insulin secretion index
      (HOMA-B using fasting glucose and C-peptide), insulinogenic index [(C-peptide at 30 min post
      OGTT - C-peptide at 0 min)/(glucose at 30 min post OGTT - glucose at 0 min)] and disposition
      index (insulinogenic index x M-value)), the lipid profile, blood pressure and anthropometric
      measurements (weight, waist and hip circumference, fat mass by dual-energy X-ray
      absorptiometry). Questionnaires on physical activity and sunlight exposure, and a food
      frequency questionnaire will be administered at 0 and 6 mo to adjust for confounding
      factors. At 0 and 6 mo, biochemical markers associated with insulin sensitivity will be
      measured (point 2).

      Part 2: Mechanistic studies comparing, before and after vitamin D3 supplementation, changes
      in serum 25(OH)D with changes in blood markers associated with insulin sensitivity [hs-CRP,
      inflammatory cytokines (IL-6 and TNF-alpha), adiponectin, leptin, total and
      undercarboxylated osteocalcin].
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change from baseline in peripheral insulin sensitivity at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose homeostasis at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes from baseline in cytokines/adipokines at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Vitamin D-deficient</condition>
  <condition>Insulin-resistant</condition>
  <arm_group>
    <arm_group_label>Vitamin D supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5000 UI vitmamin D supplementation for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Vitamin D supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian men and postmenopausal women (absence of menstrual cycles for ≥12 mo)

          -  ≥50 yrs

          -  vitamin D deficiency [serum 25(OH)D concentration ≤50 nM]

          -  hypertriglyceridemic waist phenotype (waist circumference &gt;90 cm plus fasting
             triglycerides &gt;2.0 mM in men; waist circumference &gt;85 cm plus fasting triglycerides
             &gt;1.5 mM in women)

        Exclusion Criteria:

          -  Type 2 diabetes under drug therapy

          -  HbA1c &gt;7%

          -  BMI &gt;40 kg/m2

          -  medication influencing vitamin D or glucose metabolism in the last 3 mo (including
             estrogen replacement)

          -  regular consumption of supplements containing &gt;400 IU/d of vitamin D3 over the last 2
             mo; renal insufficiency

          -  cirrhosis, intestinal malabsorption (bypass surgery, celiac disease, etc) or
             osteoporosis

          -  history of nephrolithiasis

          -  hypercalcemia (&gt;2.6 mM)

          -  hypercalciuria (&gt;0.6 fasting urine Ca/creatinine ratio)

          -  &gt;5% change in weight in the last 3 mo

          -  diseases affecting glucose metabolism (e.g. hyperthyroidism)

          -  pacemaker (for bio-impedance only)

          -  inability to provide informed consent and complete questionnaires due to physical or
             mental problems
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Gagnon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie Morisset, PhD</last_name>
    <phone>1-418-525-4444</phone>
    <phone_ext>48729</phone_ext>
    <email>anne-sophie.morisset@crchul.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Gagnon, Dr</last_name>
    <phone>1-418-525-4444</phone>
    <phone_ext>48535</phone_ext>
    <email>claudia.gagnon@crchuq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Québec, Laval University Research Center</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verson Barbara</last_name>
      <phone>1-418-525-4414</phone>
      <email>barbara.verson@crchuq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Claudia Gagnon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.vidir.ca</url>
  </link>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>January 29, 2013</lastchanged_date>
  <firstreceived_date>January 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D supplementation</keyword>
  <keyword>Insulin resistance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
